Myricyl alcohol

Synopsis

Myricyl Alcohol (1-Triacontanol): A Comprehensive Reference

1. Identity, Nomenclature, and Chemical Properties

1.1 Names and Synonyms

1-Triacontanol (n-triacontanol) is a fatty alcohol of the general formula C₃₀H₆₂O, also known as melissyl alcohol or myricyl alcohol. Additional synonyms in scientific and commercial literature include triacontyl alcohol, 1-hydroxytriacontane, and the abbreviation TRIA. Its CAS number is 593-50-0, and its registered synonyms include FOH 30:0, melissyl alcohol, myricyl alcohol, TRIA, triacontanol, and triacontyl alcohol.

1.2 Chemical Structure and Physical Properties

1-Triacontanol is a straight-chain C30 primary alcohol. It belongs to the broader chemical family of long-chain fatty alcohols, sometimes called higher aliphatic alcohols or policosanol constituents. These alcohols are waxy solids at room temperature, exhibiting low solubility in water but high solubility in organic solvents such as ethanol and chloroform. The extreme water insolubility of myricyl alcohol is of particular significance for formulation: the long-chain alcohol is very insoluble in water and in most other solvents, which has historically posed challenges for its agricultural and experimental application. The use of 1-triacontanol and the examination of the mechanism of its activity is very difficult as this compound is highly lipophilic and hardly dissolves in water.

It occurs naturally as its palmitate ester in plant cuticle waxes and beeswax. This palmitate ester form — myricyl palmitate — is the form most commonly found in biological matrices. A major component of beeswax is myricyl palmitate, which is an ester of triacontanol and palmitic acid.

1.3 Relationship to Policosanol

Myricyl alcohol is a constituent of the natural mixture known commercially as policosanol. The aliphatic alcohols present in policosanol include docosanol (C-22), tetracosanol (C-24), hexacosanol (C-26), octacosanol (C-28), nonacosanol (C-29), triacontanol (C-30), dotriacontanol (C-32), and tetratriacontanol (C-34), which are only stable in nature as a mixture. In extracts derived from sugarcane wax, the mixture is dominated by octacosanol (C₂₈H₅₈O), which typically comprises 60–70% of the total policosanol content, followed by triacontanol (C₃₀H₆₂O) at around 10–15%, hexacosanol (C₂₆H₅₄O) at 5–10%, and lesser amounts of other homologues.

2. Natural Sources and Botanical Occurrence

2.1 Plant Sources

Myricyl alcohol, also known as 1-triacontanol, is a long-chain fatty alcohol found naturally in plant waxes, especially in the cuticular waxes of leaves and stems. Triacontanol is found in various plant species as a minor component of the epicuticular wax. In wheat, triacontanol is about 3–4% of the leaf wax. More specifically, TRIA naturally occurs in epicuticular waxes in diverse plant species, such as Croton californicus, Copernica cerifera, Medicago sativa, Jatropha curcas, Oryza sativa, and Vaccinium ashei.

The alfalfa plant (Medicago sativa) is particularly noted as a rich and practically important source. Triacontanol was first isolated in 1933 from alfalfa wax. Alfalfa remains the primary plant used in research extracts and early agricultural formulations. Other sources in the policosanol context include: beeswax, wheat, sorghum, maize, rice, broccoli, spinach, alfalfa, and other cereal grains.

2.2 Occurrence in Beeswax

Yellow beeswax contains cerolein, a mixture of fatty acids and soluble in hot alcohol and slightly soluble in cold alcohol; myricyl alcohol and myricyl palmitate, insoluble in alcohol. Typically, beeswax as a raw material contains more than 300 chemical compounds, such as hydrocarbons, esters of fatty acids, and long chain alcohols. Myricyl alcohol is thus a naturally occurring, if minor, component of traditional beeswax preparations.

3. Historical Discovery and Early Research

3.1 Isolation and Chemical Identification

1-Triacontanol, the primary alcohol having 30 carbon atoms, was separated and identified by Chibnall in 1933. This early isolation established its chemical identity, but its biological activity in animals or humans was not systematically investigated for several decades. Historically, myricyl alcohol was isolated in the 19th century from natural sources, where it was first identified as a constituent of the protective waxy coatings on plant leaves.

3.2 Recognition as a Plant Growth Regulator (1970s)

The plant growth regulatory activity of triacontanol (TRIA) was first discovered by Ries et al. (1977) in alfalfa (Medicago sativa L.). In the 1970s, 1-triacontanol was identified as the active growth-promoting compound in extracts from alfalfa meal. Ries et al. (1977) isolated a crystalline substance from chloroform extracts of alfalfa (Medicago sativa L.) that enhanced the growth and yield of multiple plant species, and confirmed its identity as 1-triacontanol through mass spectrometry analysis. This breakthrough prompted the development of patents for its application as a plant growth regulator, including formulations for foliar sprays to stimulate crop productivity.

The landmark 1977 Science paper described the application to field corn of a solution containing 0.01 milligram per liter up to 1.00 milligram of triacontanol per liter. This discovery galvanized worldwide interest, particularly in Asia.

3.3 Traditional Use of Wax-Containing Preparations

Myricyl alcohol as an isolated compound does not feature prominently in historical monographs of traditional herbal medicine systems such as Ayurveda, Traditional Chinese Medicine, or European herbalism. Its traditional use is primarily indirect, through the use of beeswax-containing preparations and plant wax-rich balms. In traditional herbal medicine, myricyl alcohol-containing waxes were often components of ointments, balms, and healing salves. These preparations were applied to the skin to promote healing, reduce inflammation, and protect wounds, leveraging the emollient and barrier-forming qualities. Beeswax itself has an extensive history of use in traditional cultures: secreted by worker bees from special glands on their abdomens, this versatile wax has been used by humans for thousands of years — from ancient Egyptian mummy wrappings to modern-day cosmetics and food products.

It is important to note that in these traditional contexts, myricyl alcohol was never intentionally isolated or identified as an active principle. The therapeutic attribution to myricyl alcohol specifically is a product of modern analytical chemistry, not historical ethnopharmacology. Any health benefits observed from beeswax or alfalfa-based preparations in traditional settings cannot be specifically attributed to myricyl alcohol alone.

4. Key Constituents and Structural Context

4.1 The Policosanol Matrix

When myricyl alcohol is encountered as a dietary supplement, it is almost invariably as part of the policosanol mixture rather than as a purified single compound. The major components of the policosanol mixture are octacosanol (66%), triacontanol (12%), and hexacosanol (7%). Research on the specific biological effects of myricyl alcohol/triacontanol as an isolated compound, separate from the policosanol mixture, is limited, and care must be taken when interpreting results attributable to the whole policosanol mixture.

4.2 Relationship to the Ester Form

In natural matrices, myricyl alcohol often exists esterified to palmitic acid as myricyl palmitate. Triacontanylpalmitate is the main component of beeswax. Palmitic acid (C16:0) is esterified by a C30 chain, triacontanol (or melissyl alcohol). Whether free triacontanol or its ester form is the biologically active species in a given context is not always established in the literature.

5. Mechanisms of Action

5.1 Antioxidant and Anti-Lipid Peroxidation Activity

The most mechanistically well-characterized biological activity of triacontanol in laboratory systems is its capacity to inhibit lipid peroxidation. The effect of the plant growth regulator, triacontanol (TRIA), on lipid peroxidation was studied in three different systems: (i) isolated chloroplasts of spinach leaves; (ii) egg lecithin liposomes; and (iii) the soybean lipoxygenase (LOX) system. The nonenzymatic lipid peroxidation in isolated chloroplasts and egg lecithin liposomes was measured as the amount of thiobarbituric acid reactive substances (TBARS) formed. Inhibition of Fe²⁺ and/or light-induced lipid peroxidation by TRIA was observed in both isolated chloroplasts and egg lecithin liposomes.

The kinetics of soybean lipoxygenase-1 (LOX-1) was studied using linoleic acid as the substrate. The enzyme was competitively inhibited by TRIA. The Ki for TRIA inhibition of the enzyme was estimated to be 3.2–5.0 µM according to different methods of estimation. TRIA has been known to exhibit anti-inflammatory action in animals and this anti-inflammatory effect of TRIA might be mediated through inhibition of lipid peroxidation pathways. This in vitro work (PubMed PMID: 11021645) provides a mechanistic basis for the anti-inflammatory observations, though it was conducted in cell-free or plant-based systems.

5.2 Anti-Inflammatory Mechanisms

Triacontanol can prevent oxidative stress, induce anti-inflammatory responses and inhibit lipid peroxidation. Specifically, laboratory research has indicated that TA could inhibit the proliferation and metastasis of cancer cells, via inhibiting cyclooxygenase 2 (COX-2) and vascular endothelial growth factor (VEGF). COX-2 inhibition is a well-established mechanism by which many natural and synthetic compounds reduce inflammatory signaling. These findings are, to date, derived from preclinical (cell line and animal) studies.

5.3 Immune Modulation

Research in animal models and cell cultures has identified preliminary immunomodulatory effects. It could promote spleen lymphocyte proliferation, then improve immune system via activating natural killer cells and facilitate macrophage phagocytosis. When applied in combinational therapy, TA significantly counteracted leukopenia induced by cyclophosphamide. A pharmacokinetic study noted that tissue exposure to TA in spleen ranked the largest, reaching 4171 ng/g tissue. And the spleen serves as the largest immune organ and participates in various immune responses. TA has also been reported to significantly promote the proliferation of mouse spleen lymphocytes and participate in the body's immune regulation. Therefore, the largest distribution to spleen was of great significance in improving the immune function and exerting anti-tumor activity.

5.4 Plant-Specific Mechanisms (Context)

Much of the published mechanistic literature on triacontanol concerns plants rather than human biology. For context, triacontanol has been reported to increase the growth of plants by enhancing the rates of photosynthesis, protein biosynthesis, the transport of nutrients in a plant and enzyme activity, reducing complex carbohydrates among many other purposes. The fatty alcohol appears to increase the physiological efficiency of plant cells and boost the potential of the cells responsible for the growth and maturity of a plant. These plant mechanisms are not directly transferable to human physiology and are cited here only to contextualize the body of triacontanol science.

6. Scientific Evidence by Area of Use

6.1 Anti-Inflammatory Activity

Evidence type: Animal (guinea pig model) — Preliminary

A mixture of the aliphatic alcohol, triacontanol, and other chemically associated naturally occurring alcohols was applied to the denuded dorsal cutaneous surface of guinea pigs to evaluate anti-inflammatory activity. In the setting of a chemical irritation with 2% croton oil and in an allergic dermatitis created with dinitrochlorobenzene sensitization and challenge, the triacontanol-containing preparation was significantly more effective than vehicle alone (DHL skin cream) but not as effective as 0.05% Diprolene ointment. Lymphocyte stimulation was studied by tritiated thymidine uptake and morphologic examination for blast transformation. When triacontanol-containing compounds were solubilized in aqueous media, effects on lymphocytes were insignificant. When solubilized in ethanol, there was a marked effect on thymidine uptake but not on blast transformation when compared to parallel controls.

This PubMed-indexed study (PMID: 3668280) is an animal model study using a mixture of alcohols, not purified triacontanol alone. No controlled human clinical trials on topical anti-inflammatory effects of myricyl alcohol have been identified in the peer-reviewed literature. The evidence for anti-inflammatory activity in humans must therefore be characterized as unestablished — with animal/in vitro preliminary support only.

6.2 Antioxidant Activity

Evidence type: In vitro — Preliminary

As described in Section 5.1, in vitro evidence demonstrates that triacontanol competitively inhibits the enzyme lipoxygenase-1 (with Ki of 3.2–5.0 µM) and inhibits both enzymatic and nonenzymatic lipid peroxidation in model membrane systems. n-Triacontanol has been identified as a plant growth regulator with plant growth-stimulating and antioxidant activities. However, no peer-reviewed randomized controlled trials in humans examining the antioxidant activity of isolated triacontanol have been identified. The antioxidant evidence base is confined to in vitro biochemical assays.

6.3 Anti-Neoplastic / Anti-Cancer Potential

Evidence type: In vitro and animal — Highly preliminary

Research at the China Pharmaceutical University explored the anti-neoplastic potential of triacontanol and a PEGylated derivative. PEG-TA conjugate displayed superior anti-neoplastic activities and low toxicity, as well as facilitated the delivery of other hydrophobic agents, which appeared to be an innovative strategy for cancer therapy. These investigators noted that native triacontanol, being poorly water-soluble, has limited bioavailability for systemic anti-cancer applications. TA exhibits no toxic effects on humans or animals, no contaminative risk to environment since it mostly exists in waxy plants and insects.

Separately, preclinical research confirmed that triacontanol was confirmed to have a potential anti-cancer effect in rat-based experiments, though these were conducted specifically to assess drug–drug interaction risks with the chemotherapy agent docetaxel, not to directly characterize anti-tumor efficacy.

No human clinical trials of triacontanol for cancer treatment or prevention have been identified in the peer-reviewed literature. All anti-cancer evidence is at the in vitro or animal stage and is highly preliminary. Claims of anti-cancer activity in humans are not supported by current evidence.

6.4 Cardiovascular / Lipid Profile Effects

Evidence type: Indirect (policosanol mixture) — Conflicting

Most cardiovascular research on long-chain aliphatic alcohols has been conducted on the policosanol mixture as a whole, with octacosanol (C28) receiving the most investigative attention. Several reports, including many clinical trials, have shown that policosanols have significant health-promoting activities such as the reduction of lipid levels, platelet aggregation reduction, antiviral activity, reduction of prostate enlargement, and relief of intermittent claudication. In contrast, there are conflicting findings about the efficacy of policosanol, particularly with regard to lowering lipid levels. The specific contribution of triacontanol to these effects, separate from other policosanol constituents, has not been isolated in clinical research. Any cardiovascular claims specific to myricyl alcohol/triacontanol lack direct clinical substantiation.

6.5 Plant Growth and Agronomic Applications

Evidence type: Multiple agricultural studies — Established for plants; not applicable to human health

Triacontanol's most robustly documented biological effects are in plant science. It has been widely used to enhance the yield of various crops around the world, mainly in Asia. Studies confirm effects on chlorophyll synthesis, photosynthesis rates, and enzyme activity in a range of crops. However, it is important to note that field testing of various triacontanol formulations has generally produced inconsistent and disappointing results, with formulation challenges (particularly around the compound's insolubility) frequently cited as confounding factors. These agronomic findings have no direct relevance to human dietary supplementation.

7. Body Systems and Health Areas Associated with Myricyl Alcohol

7.1 Immune System

Preclinical evidence suggests myricyl alcohol distributes preferentially to immunological tissues. TA has been reported to significantly promote the proliferation of mouse spleen lymphocytes and participate in the body's immune regulation. Therefore, the largest distribution to spleen was of great significance in improving the immune function and exerting anti-tumor activity. This is animal-based evidence only; no human immunological trials have been conducted.

7.2 Integumentary System (Skin)

Historical use of beeswax and plant wax preparations — containing myricyl alcohol as a constituent — for topical skin conditions is documented. A topical pharmaceutical composition comprising 1-triacontanol as active ingredient is useful for treating skin disorders, according to a cited European patent application. Animal model data demonstrate anti-inflammatory activity on skin when triacontanol-containing preparations are applied topically. Human clinical evidence specific to myricyl alcohol's dermatological applications has not been identified in the peer-reviewed literature.

7.3 Anti-Inflammatory / Musculoskeletal

The inhibition of lipoxygenase and lipid peroxidation provides a mechanistic framework for potential anti-inflammatory effects. The guinea pig skin model study (PMID: 3668280) is the most direct animal study relevant to inflammatory conditions. No human clinical trials for inflammatory joint conditions or systemic inflammation have been identified.

7.4 Oncology (Preclinical Interest)

As summarized in Section 6.3, interest in triacontanol as an adjunct or novel scaffold for anti-cancer drug development is emerging, based on in vitro and animal data involving COX-2 and VEGF inhibition, immunostimulation, and improved formulations using PEGylation. This remains a research-stage topic.

8. Common Forms, Preparations, and Dosage

8.1 Natural Forms

Myricyl alcohol is encountered in nature primarily as a constituent of plant cuticular waxes and as the ester myricyl palmitate in beeswax. Triacontanol is a fatty alcohol that is also known as melissyl alcohol or myricyl alcohol. It can be derived from plant cuticle waxes and beeswax and other sources. As a dietary supplement, it is most commonly encountered within commercial policosanol preparations, usually extracted from sugarcane wax, rice bran wax, or beeswax.

8.2 Dosage Forms

Purified triacontanol is commercially available as a research-grade chemical at ≥98% purity. In the context of plant biology research, foliar spray preparations at concentrations in the range of 0, 1, 5, and 10 µM have been evaluated in controlled greenhouse studies, with a dose of 10 µM TRIA being the most efficient concentration in one rice transplanting study.

In the preclinical pharmacokinetic study concerning drug interactions (rat model), triacontanol preferentially induced protein expression level of CYP3A2 in a dose-dependent manner and of CYP3A1 at dosages of 120 and 180 mg kg⁻¹. These are high experimental doses in rats and do not correspond to human supplemental intake.

For the anti-neoplastic PEG-conjugate research, triacontanol of purity >95% was used in pharmacological evaluations. No human dosage protocols for isolated myricyl alcohol/triacontanol have been established in peer-reviewed clinical trials.

Within policosanol mixture supplements, triacontanol is a minor component. Policosanol is a mixture of long-chain primary aliphatic alcohols with octacosanol comprising the majority (up to 66%) of its composition, alongside other components such as triacontanol (12%) and hexacosanol (7%). Policosanol supplements are typically standardized and marketed at 5–20 mg daily doses of the whole mixture, meaning triacontanol intake in this context would typically be well under 3 mg per dose. These figures are drawn from the composition literature, not from dosage studies on myricyl alcohol specifically.

9. Safety Considerations and Drug Interactions

9.1 General Safety Profile

Based on available preclinical evidence, myricyl alcohol appears to have a low acute toxicity profile. TA exhibits no toxic effects on humans or animals, no contaminative risk to environment since it mostly exists in waxy plants and insects. However, formal human toxicology studies have not been identified in the peer-reviewed literature, and regulatory agencies have not issued specific monographs on isolated myricyl alcohol/triacontanol as a dietary supplement ingredient.

From a regulatory safety standpoint, the US EPA PC Code for 1-triacontanol is 116201 (assigned in its capacity as a registered plant growth regulator). The PesticideInfo database classifies it as insufficiently studied with respect to reproductive and developmental toxicology, and also as insufficiently studied as a cholinesterase inhibitor. This designation reflects data gaps rather than established hazards, but underscores the limited scope of formal toxicological evaluation.

9.2 Cytochrome P450 Enzyme Interactions

A specific and important pharmacokinetic safety signal has been identified in rat studies. The aim was to assess whether the co-administration of triacontanol alters the exposure of docetaxel via inducing hepatic CYP3A1/2 activity. The concentration of docetaxel in rats pretreated with triacontanol for seven successive days was determined, and the expression levels of CYP3A protein and mRNA were analyzed by western blot and real time polymerase chain reaction (RT-PCR) technique.

The results were significant: the concentrations of docetaxel in rats pretreated with triacontanol were decreased, with 61.5%, 61.9% decrease in AUC₀₋₂₄h and 65.7%, 54.9% reduction in Cmax (at 120 and 180 mg kg⁻¹, respectively) compared with the control. The investigators concluded that the significant triacontanol-docetaxel interaction was largely due to the induction of CYP3A1/2, which brought useful information in the clinical therapy when the combination is administered in human.

This preclinical finding indicates that triacontanol, at high doses, can induce cytochrome P450 CYP3A enzymes in rats — the rodent homologues of the human CYP3A4 enzyme, which metabolizes a very large proportion of clinically used drugs (including many chemotherapy agents, immunosuppressants, and cardiovascular drugs). Whether this induction occurs at the far lower doses encountered in human supplemental use has not been established in human pharmacokinetic studies. The finding was published in Xenobiotica (2014, PMID: 24329500) and constitutes a specific, source-backed interaction signal that warrants attention, particularly in the context of oncology patients who might co-administer triacontanol supplements with taxane-based chemotherapy.

9.3 Solubility, Formulation, and Bioavailability Concerns

Bioavailability of policosanol was reported to be between 5% and 12%, with absorption after oral administration ranging from correspondingly low levels. The poor water solubility of myricyl alcohol is a fundamental limiting factor for its biological activity following oral ingestion. The long-chain alcohol is very insoluble in water and in most other solvents. Ries and others have used combinations of solvents, detergents and surfactants in efforts to keep triacontanol in solution. The formulation vehicle used significantly affects pharmacological outcomes: solubilization in ethanol, for example, produced markedly different lymphocyte responses compared to aqueous preparations in the cited guinea pig study.

9.4 Insufficient Formal Regulatory Evaluation

No specific monograph for myricyl alcohol/1-triacontanol as a human dietary supplement has been identified from major regulatory bodies including the NIH Office of Dietary Supplements, the European Medicines Agency (EMA), or the European Food Safety Authority (EFSA). The compound is not listed in the WHO monographs on selected medicinal plants, the German Commission E monographs, or ESCOP monographs as an isolated ingredient. Its use in food is primarily as a constituent of beeswax, which carries GRAS (Generally Recognized as Safe) status in the United States — but this designation applies to the complex beeswax matrix, not to isolated myricyl alcohol.

10. Current Research Status and Evidence Gaps

The scientific literature on myricyl alcohol as a bioactive compound in human health remains sparse and preliminary. Key evidence gaps include:

No published randomized controlled trials in humans for any health indication.
No established human pharmacokinetic profile for oral triacontanol supplementation at typical dietary supplement doses.
No formal dose-finding studies in humans.
No systematic reviews or meta-analyses specific to isolated triacontanol health effects.
Most published evidence is from plant biology (growth regulation), in vitro biochemical assays, or rodent models.
The drug interaction signal (CYP3A induction) observed in rats has not been confirmed or refuted in human pharmacokinetic studies.

Emerging research is focused primarily on formulation science (e.g., PEGylation, nanoemulsions) to overcome the bioavailability barrier, and on preclinical evaluation of anti-cancer mechanisms. The present study innovatively attempted to chemically modify TA through attaching PEG to overcome its solubility barrier based on prodrug strategy, to achieve the superior anti-neoplastic activities of TA. Meanwhile, the pharmacokinetics, pharmacodynamics, and safety evaluation of the newly prepared triacontanol derivative was performed to demonstrate the advantages of the compound.

In the agricultural domain, the compound has a longer and more established track record, but even there, field results have been inconsistent. As noted by Ries and subsequent investigators, field testing of various triacontanol formulations has generally produced inconsistent and disappointing results.

Summary

Myricyl alcohol (1-triacontanol) is a naturally occurring C30 saturated primary fatty alcohol found in plant cuticular waxes and beeswax, most prominently in alfalfa. First isolated in 1933 and identified as a plant growth regulator in 1977, it is a minor constituent (approximately 10–15%) of the commercially used policosanol mixture. In vitro and animal research supports antioxidant activity (via lipoxygenase inhibition and suppression of lipid peroxidation), anti-inflammatory activity (via animal skin models), immunomodulatory potential (via spleen lymphocyte proliferation in rodents), and preliminary anti-neoplastic effects (via COX-2 and VEGF inhibition in cell culture). A specific and important preclinical pharmacokinetic concern is its induction of CYP3A enzymes in rats, which significantly reduced docetaxel plasma exposure. No human clinical trials exist for any health indication. The overall human health evidence base is preliminary, is derived from non-human systems, and does not yet support definitive efficacy conclusions for any therapeutic or supplemental application.